Albert M. Maguire - Concepedia

Author

Albert M. Maguire

Also Known As

A M Maguire, A Maguire, A. M MAGUIRE, A. M. Maguire, A. Maguire, A.M. Maguire, ALBERT M. MAGUIRE, ALBERT MAGUIRE, Albert M Maguire, Albert M. Maguire

259

Publications

19.8K

Citations

H-Index

113

Concepts

All Affiliations

Penn Presbyterian Medical Center University of Pennsylvania Children's Hospital of Philadelphia Telethon Institute Of Genetics And Medicine University of Naples Federico II

About

Albert M. Maguire is an author at Penn Presbyterian Medical Center specializing in medicine, ophthalmology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	34	48	10.3K
2	Engineering	3	3	145
3	Natural Sciences	3	3	562
4	Health Sciences	2	2	57
5	Public Health	1	1	12

Albert M. Maguire

122

Publications

18.2K

Citations

H-Index

Page 1

	Year	Citations
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis Albert M. Maguire, Francesca Simonelli, Eric A. Pierce, New England Journal of Medicine Ocular DiseaseGeneticsImmunologyPathologyDisease Gene Identification	2008	2.1K
Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65 -mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial Stephen R. Russell, Jean Bennett, Jennifer Wellman, The Lancet Ocular DiseaseRetinaOphthalmologyExperimental OphthalmologyVoretigene Neparvovec	2017	1.8K
Gene therapy restores vision in a canine model of childhood blindness Gregory M. Acland, Jharna Ray, Qí Zhāng, Nature Genetics OptogeneticsGene TherapiesDevelopmental BiologyRetinaOphthalmology	2001	1.2K
Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial Albert M. Maguire, Katherine A. High, Alberto Auricchio, The Lancet Gene TherapiesGenetic DisorderGeneticsClinical TrialsTranslational Research	2009	849
Gene Therapy for Leber's Congenital Amaurosis is Safe and Effective Through 1.5 Years After Vector Administration Francesca Simonelli, Albert M. Maguire, Francesco Testa, Molecular Therapy	2009	544
Genetic variants near <i>TIMP3</i> and high-density lipoprotein–associated loci influence susceptibility to age-related macular degeneration Wei Chen, Dwight Stambolian, Albert O. Edwards, Proceedings of the National Academy of Sciences	2010	511
Long-Term Restoration of Rod and Cone Vision by Single Dose rAAV-Mediated Gene Transfer to the Retina in a Canine Model of Childhood Blindness Gregory M. Acland, Jean Bennett, Tomás S. Alemán, Molecular Therapy	2005	464
Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial Jean Bennett, Jennifer Wellman, Kathleen Marshall, The Lancet Translational MedicineGene TherapiesOcular DiseaseAav2 Gene TherapyIn Vivo Gene Therapy	2016	445
Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Samuel J. Reich, Joshua Fosnot, A. Kuroki, PubMed	2003	439
AAV2 Gene Therapy Readministration in Three Adults with Congenital Blindness Jean Bennett, Manzar Ashtari, Jennifer Wellman, Science Translational Medicine Gene TherapiesTranslational MedicineRpe65 GeneRetinaIn Vivo Gene Therapy	2012	387

Page 1